Leaning Objectives
Upon completion of this activity, you should be able to:
- Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with HF to determine best practices for care.
- Distinguish pathophysiologic characteristics of current classifications of phenotypes when diagnosing HF to analyze best HF risk stratification, prevention, and management strategies.
- Incorporate GDMT, newer therapies, and interprofessional team strategies into treatment care plans for the management of HF to improve care coordination, communication, and patient outcomes.
Faculty
Leslie L. Davis, NP, PhD, FACC
University of North Carolina
Chapel Hill, North Carolina
Katherine Crawford, PharmD, BCCP, AACC
Riverside Methodist Hospital
Target Audience
The primary target audience for this education are members of the HF Care Team, including physicians, advanced practice providers (APPs), PharmDs, and other HCPs.
Important Dates
Date of Release: December 18, 2025
Term of Approval/Date of Expiration: December 15, 2026
Acknowledgement
This activity is supported by an unrestricted educational grant from Bayer AG.